Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes (ARTiDe)

Projektinformationen

ARTiDe

ID Finanzhilfevereinbarung: 101080823

DOI

10.3030/101080823

EK-Unterschriftsdatum 27 April 2023

Startdatum 1 Juli 2023

Enddatum 30 Juni 2028

Finanziert unter

• Health

Gesamtkosten

€ 6 998 037,50

EU-Beitrag

€ 6 998 037,50

Koordiniert durch

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France

Periodic Reporting for period 1 - ARTiDe (Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes (ARTiDe))

Berichtszeitraum: 2023-07-01 bis 2024-12-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

The ARTiDe project aims to develop an innovative therapy for type 1 diabetes (T1D) by engineering regulatory T lymphocytes (Tregs) to suppress autoimmunity. By integrating advanced immunological research, genetic engineering, and clinical translation, ARTiDe seeks to enhance personalized immunotherapy for T1D patients. The project involves characterizing T cell responses, evaluating the efficacy and safety of engineered Tregs, developing strategies to maintain their suppressive function, and advancing genetic modification processes for clinical application. Additionally, a comprehensive communication and effective management strategy is implemented to maximize the project's scientific and societal impact.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The consortium partners are actively collaborating to achieve the ARTiDe project's objectives, ensuring steady progress across all work packages. They have characterized Treg responses to β-cell antigens, developed insulin-specific TCRs, and established a humanized mouse model for testing. Additionally, partners are working on nanoparticles to stimulate regulatory T cells and optimizing clinical-grade processes for Treg modification. The project has also developed its identity and communication materials, established an Innovation Management Board for IP management, and ensured efficient project management and reporting. Through these efforts, ARTiDe is making significant strides toward developing a T cell-based therapy for T1D, integrating advanced immunological research, genetic engineering, and clinical translation.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

At this stage of the ARTiDe project, significant milestones have been achieved. A breakthrough analysis pipeline has been developed to characterize Treg responses against β-cell antigens and identify related TCR sequences, providing a solid foundation for further validation and analysis. The project has the potential to establish a first of its kind highly targeted therapy for T1D, with a tailored preclinical model that could standardize antigen-specific immune therapies. Preliminary results also suggest that proinsulin-carrying nanoparticles selectively accumulate in pancreatic islets, attracting T lymphocytes and reducing islet inflammation.